한국어
Quantus

Sam-A Pharm.

009300 · KOSDAQ
₩14,000+0.36%
2026-09-04 close

Sam-A Pharm. last closed at ₩14,000 (+0.36%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.

Loading chart…
Close
No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p

Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

A-
Overall: 건강관리 67/291 · top 23%
Factor composite · relative position in sector

PER 4.04 · PBR 0.41 — own-history percentile 97/100 · 95/100

Open self-history band
PER97/100
PBR95/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Annual dividend

Split-adjusted annual DPS history and available grade axes

Annual dividend per share chart2000: 196원20002001: No dividend paid2002: 245원2003: 59원2004: 196원2005: 196원20052006: 196원2007: 196원2008: 196원2009: 100원2010: 150원20102011: 200원2012: 200원2013: 200원2014: 200원2015: 200원20152016: 200원2017: 250원2018: 250원2019: 250원2020: 300원20202021: 300원2022: 250원2023: 400원2024: 750원2025: 800원800원2025
Annual dividend (per share · split-adjusted) · as of 2025
Consistency
A
Growth
A+
Yield
A
Safety
A+
Reference indicatorView observed cut rates

Paid 24 consecutive years · Raised 3 consecutive years · Yield 5.71% (based on 2025 payment of 800원) · 3-year growth +47.4%

Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 13.71
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
13.71
Beneish M-Score
-2.56

No statistical flag

Sloan accrual
-1.27%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

6/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score6/9

Profitability

  • Positive ROAPass
  • Positive OCFPass
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioNot passed
  • No new sharesPass

Efficiency

  • Higher gross marginPass
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Industry structure

KRAs of 2026-09-05

건강관리

This stock is in 건강관리: revenue rank 120 of 287, share 0.2%.

120 / 2870.2%revenue share

Who dominates this industry?

  1. 1삼성바이오로직스7.3%
  2. 2셀트리온5.7%
  3. 3녹십자홀딩스3.5%
  4. 4유한양행3.3%
  5. 5대웅3.1%
  6. 6삼아제약0.2%

Concentration

DistributedCR3 16.6%
HHI 202287 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
31.61
Direction
확대
Level
넓음
Years
7

Value lens

P90/P10
13.9
Median P/B
1.47
Level
넓음
n
263

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
25.6%
Interest coverage
45.5x
Return on equity (ROE)
10%

Operating margin −5pp

Tolerable
Interest coverageBase 45.5x adverse case 36.6x
Return on equity (ROE)Base 10% adverse case 8.7%

Revenue −15%

Tolerable
Interest coverageBase 45.5x adverse case 38.6x
Return on equity (ROE)Base 10% adverse case 9.2%

Interest rate +2pp

Tolerable
Interest coverageBase 45.5x adverse case 22x
Return on equity (ROE)Base 10% adverse case 10.6%

Interest coverage limit

Current margin 25pp

Interest coverage limit at an operating margin of 0.6%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-04-22

Suppliers disclosed by the company in its 2026-04-22 annual report.

Suppliers without disclosed amount

ALPSDiviSiegfriedFinzelbergUSDEURJPYSGD

Connections

AI-extracted related companies · for reference

Same theme
종근당건강
🔗 See in the full market map →

Recent filings

Sam-A Pharm.'s latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

About Sam-A Pharm.
What technical signals does Sam-A Pharm. (009300) have?
Sam-A Pharm. current technical signals: no active technical signal.
Is Sam-A Pharm. a cup-and-handle pattern?
No. Sam-A Pharm. has no valid cup-and-handle signal right now.
What are Sam-A Pharm.'s financials and valuation?
Sam-A Pharm.'s income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy